Published in PLoS One on December 19, 2012
Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE) (PROMOTE) | NCT05155137
Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev (2014) 2.24
Polypill therapy, subclinical atherosclerosis, and cardiovascular events-implications for the use of preventive pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2013) 1.60
Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res (2014) 0.93
Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open (2013) 0.81
[Polypharmacy and drug prescription in the elderly. Strategies for optimization]. Z Gerontol Geriatr (2014) 0.78
Single-pill combinations: a therapeutic option or necessity for vascular risk treatment? J Drug Assess (2013) 0.75
Prevention: Polypills for cardiovascular prevention: a step forward? Nat Rev Cardiol (2013) 0.75
Could patents interfere with the development of a cardiovascular polypill? J Transl Med (2016) 0.75
Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One (2017) 0.75
Practical Applications for Single Pill Combinations in the Cardiovascular Continuum. Card Fail Rev (2017) 0.75
Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. High Blood Press Cardiovasc Prev (2017) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
A strategy to reduce cardiovascular disease by more than 80%. BMJ (2003) 19.05
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Preventing chronic diseases: how many lives can we save? Lancet (2005) 14.77
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ (2003) 11.21
Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ (2003) 8.55
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2009) 7.34
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (2001) 7.13
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (2009) 6.83
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 5.17
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet (2007) 4.15
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol (2006) 3.30
Two decades of progress in preventing vascular disease. Lancet (2002) 3.30
Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med (2005) 3.19
The Health Impact Fund: incentives for improving access to medicines. Lancet (2010) 2.99
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract (2010) 2.57
Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension (2009) 2.28
Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med (2010) 2.11
Randomized Polypill crossover trial in people aged 50 and over. PLoS One (2012) 1.64
Long-term adherence with cardiovascular drug regimens. Am Heart J (2006) 1.52
The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation (2010) 1.51
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34
A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials (2011) 1.27
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes (2012) 1.24
Which interventions offer best value for money in primary prevention of cardiovascular disease? PLoS One (2012) 1.15
Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp Clin Trials (2010) 1.07
Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol (2012) 1.06
Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk. BMC Public Health (2010) 0.93
The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open (2011) 0.90
IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials (2011) 0.90
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) (2009) 0.87
The cardiovascular polypill in high-risk patients. Eur J Prev Cardiol (2011) 0.85
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgrad Med (2010) 0.82
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther (2009) 0.81
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. Vasc Health Risk Manag (2010) 0.80
Cardiovascular treatment gaps: closing, but slowly. N Z Med J (2009) 0.79
Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand. Diabetes Res Clin Pract (2007) 0.77
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Selected major risk factors and global and regional burden of disease. Lancet (2002) 24.47
Global burden of blood-pressure-related disease, 2001. Lancet (2008) 11.09
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet (2011) 8.19
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet (2014) 6.23
Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet (2003) 5.26
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 5.17
Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet (2005) 5.13
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev (2012) 4.71
Rethinking the "diseases of affluence" paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med (2005) 4.64
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol (2009) 4.43
Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet (2007) 4.15
Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev (2009) 3.70
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens (2006) 3.12
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol (2005) 2.86
Comparative quantification of health risks conceptual framework and methodological issues. Popul Health Metr (2003) 2.80
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med (2014) 2.64
Honey as a topical treatment for wounds. Cochrane Database Syst Rev (2008) 2.64
Effects of active video games on body composition: a randomized controlled trial. Am J Clin Nutr (2011) 2.61
Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ (2005) 2.54
Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes. BMJ (2008) 2.48
A multimedia mobile phone-based youth smoking cessation intervention: findings from content development and piloting studies. J Med Internet Res (2008) 2.46
Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. J Hypertens (2006) 2.43
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K. Eur Heart J (2011) 2.43
Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens (2006) 2.37
Redefining Blood-Pressure Targets--SPRINT Starts the Marathon. N Engl J Med (2015) 2.30
Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials (2008) 2.26
Blood pressure and stroke: an overview of published reviews. Stroke (2004) 2.21
Blood pressure and stroke: an overview of published reviews. Stroke (2004) 2.19
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care (2013) 2.07
Effects of price discounts and tailored nutrition education on supermarket purchases: a randomized controlled trial. Am J Clin Nutr (2009) 2.01
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation (2008) 1.88
Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med (2009) 1.86
Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol (2012) 1.84
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J (2009) 1.79
Secondary prevention of cardiovascular disease: a randomised trial of training in information management, evidence-based medicine, both or neither: the PIER trial. Br J Gen Pract (2002) 1.77
Energy expended playing video console games: an opportunity to increase children's physical activity? Pediatr Exerc Sci (2007) 1.76
MEMO--a mobile phone depression prevention intervention for adolescents: development process and postprogram findings on acceptability from a randomized controlled trial. J Med Internet Res (2012) 1.71
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
A theory-based video messaging mobile phone intervention for smoking cessation: randomized controlled trial. J Med Internet Res (2011) 1.66
Smoking cessation using mobile phone text messaging is as effective in Maori as non-Maori. N Z Med J (2005) 1.66
Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet (2005) 1.64
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int (2012) 1.63
A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries. BMJ (2003) 1.60
Couch potatoes to jumping beans: a pilot study of the effect of active video games on physical activity in children. Int J Behav Nutr Phys Act (2008) 1.58
Gaps in primary care documentation of cardiovascular risk factors. N Z Med J (2008) 1.56
Cardiovascular risk factors at age 30 following pre-term birth. Int J Epidemiol (2007) 1.55
Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease. Circulation (2005) 1.55
Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus. Contemp Clin Trials (2006) 1.47
Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. Eur J Cardiovasc Prev Rehabil (2008) 1.45
Effectiveness of monetary incentives in modifying dietary behavior:a review of randomized, controlled trials. Nutr Rev (2006) 1.45
Blood pressure loci identified with a gene-centric array. Am J Hum Genet (2011) 1.44
Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Med (2013) 1.44
Elevated total cholesterol: its prevalence and population attributable fraction for mortality from coronary heart disease and ischaemic stroke in the Asia-Pacific region. Eur J Cardiovasc Prev Rehabil (2008) 1.43
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ (2013) 1.43
The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens (2011) 1.41
Venous ulcer management in New Zealand: usual care versus guideline recommendations. N Z Med J (2009) 1.40
Will a web-based cardiovascular disease (CVD) risk assessment programme increase the assessment of CVD risk factors for Maori? N Z Med J (2006) 1.39
The occurrence of leg ulcers in Auckland: results of a population-based study. N Z Med J (2002) 1.38
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer (2005) 1.37
An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One (2011) 1.34
Body mass index and risk of diabetes mellitus in the Asia-Pacific region. Asia Pac J Clin Nutr (2006) 1.33
Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation (2013) 1.32
Socio-economic distribution of cardiovascular risk factors and knowledge in rural India. Int J Epidemiol (2012) 1.30
Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis (2010) 1.27
Electrochemically controlled drug delivery based on intrinsically conducting polymers. J Control Release (2010) 1.22
Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes (2012) 1.21
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke (2005) 1.20
The PROGRESS trial three years later: time for more action, less distraction. BMJ (2004) 1.20
Leg ulceration and perceived health: a population based case-control study. Age Ageing (2004) 1.19
Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension (2003) 1.18
International Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): a doubly labelled water validation. Int J Behav Nutr Phys Act (2007) 1.16
The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. Eur J Health Econ (2012) 1.13
The HRT furore: getting the message right. Med J Aust (2002) 1.13
Pre-cessation nicotine replacement therapy: pragmatic randomized trial. Addiction (2010) 1.13
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med (2012) 1.12
Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol (2013) 1.11
Do effects of price discounts and nutrition education on food purchases vary by ethnicity, income and education? Results from a randomised, controlled trial. J Epidemiol Community Health (2011) 1.11
A randomised trial of the effects of an additional communication strategy on recruitment into a large-scale, multi-centre trial. Contemp Clin Trials (2006) 1.10
Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol (2004) 1.10